Tiziana Life Sciences Ltd
TLSAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and. The $128.5M market capitalization puts TLSA squarely in micro-cap range for its industry. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Market Cap
$128.5M
Beta
0.44
P/E (TTM)
—
P/E (Fwd)
-5.55
EPS (TTM)
$-0.21
EPS (Fwd)
$-0.18
ROE
-780.6%
ROA
-103.2%
Cash
$3.2M
Total Debt
$932,000
Free CF
-$6.4M
52W Change
-47.7%
Annual Financials
Cash vs Debt
Where TLSA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TLSA finished 13.68% below its 150-day moving average ($1.17) and 18.55% below its 200-day moving average ($1.24). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TLSA overbought or oversold?
At the October 20, 2026 close, TLSA's RSI(14) was 55.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $3.2M in cash comfortably exceeding the $932K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$6.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -780.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.44 suggests TLSA is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing TLSA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.